| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | C.H. Latta | |
| D.M. Wilcock | |||
| H.M. Brothers | |||
| P2860 | cites work | Peripheral nerve lesion produces increased levels of major histocompatibility complex antigens in the central nervous system | Q69939601 |
| Upregulation of the macrophage scavenger receptor in response to different forms of injury in the CNS | Q72469240 | ||
| Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice | Q77384367 | ||
| A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. | Q51983154 | ||
| A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. | Q53233235 | ||
| Regional distribution of cortical microglia parallels that of neurofibrillary tangles in Alzheimer's disease. | Q53234867 | ||
| Clinical trial of indomethacin in Alzheimer's disease. | Q53318286 | ||
| Comparison of polarization properties of human adult microglia and blood-derived macrophages | Q57041309 | ||
| Lectin binding by resting and reactive microglia | Q69227706 | ||
| Exploring the full spectrum of macrophage activation | Q24653754 | ||
| Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage | Q24791704 | ||
| A role for IgG immune complexes during infection with the intracellular pathogen Leishmania | Q25256801 | ||
| Inflammation and Alzheimer's disease | Q28138617 | ||
| Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial | Q28260488 | ||
| A meta-analysis of cytokines in Alzheimer's disease | Q28289922 | ||
| Macrophages and their products in rheumatoid arthritis | Q28296955 | ||
| No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial | Q28471970 | ||
| Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway | Q28571359 | ||
| IL-4 attenuates the neuroinflammation induced by amyloid-beta in vivo and in vitro | Q28582135 | ||
| A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI | Q28741766 | ||
| Alternative activation of macrophages: mechanism and functions | Q29614350 | ||
| The many faces of macrophage activation | Q29617449 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| Alzheimer's disease: clinical trials and drug development | Q33349401 | ||
| Multimodal techniques for diagnosis and prognosis of Alzheimer's disease | Q33607535 | ||
| Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. | Q33768246 | ||
| Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results | Q33836869 | ||
| NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type | Q33881607 | ||
| The phagocytes: neutrophils and monocytes | Q34013216 | ||
| Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib | Q34077849 | ||
| Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease | Q34141675 | ||
| Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype | Q34162967 | ||
| LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice | Q34173381 | ||
| Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation | Q34326460 | ||
| Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens | Q34504753 | ||
| Biochemical and functional characterization of three activated macrophage populations. | Q34556828 | ||
| Is pharmacological prevention of Alzheimer's a realistic goal? | Q34588663 | ||
| Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. | Q34659689 | ||
| Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain | Q34693537 | ||
| Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease | Q35028860 | ||
| Critical role of regulator G-protein signaling 10 (RGS10) in modulating macrophage M1/M2 activation | Q35054094 | ||
| Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD | Q35090548 | ||
| Proinflammatory clearance of apoptotic neutrophils induces an IL-12(low)IL-10(high) regulatory phenotype in macrophages | Q43820826 | ||
| Neuronal DNA damage correlates with overexpression of interleukin-1beta converting enzyme in APPV717F mice | Q43832211 | ||
| Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial | Q44463935 | ||
| Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study | Q44725520 | ||
| Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins | Q44917427 | ||
| A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment | Q45292749 | ||
| TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. | Q45972218 | ||
| A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. | Q46008345 | ||
| Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels | Q46244500 | ||
| Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. | Q46303283 | ||
| IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. | Q46305082 | ||
| Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study | Q46373170 | ||
| Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. | Q46691360 | ||
| Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. | Q47230871 | ||
| Rate of cognitive decline in preclinical Alzheimer's disease: the role of comorbidity | Q47739633 | ||
| IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors | Q47862694 | ||
| Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. | Q48377805 | ||
| The importance of inflammatory mechanisms in Alzheimer disease. | Q48380991 | ||
| Phenotyping primary human microglia: tight regulation of LPS responsiveness. | Q48458622 | ||
| Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. | Q48485596 | ||
| A novel phospholipid-based drug formulation, VP025, modulates age- and LPS-induced microglial activity in the rat. | Q48519143 | ||
| Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. | Q48825088 | ||
| An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". | Q48903618 | ||
| Extended results of the Alzheimer's disease anti-inflammatory prevention trial | Q35146385 | ||
| Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain | Q35235768 | ||
| Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial | Q35523832 | ||
| Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses | Q35581445 | ||
| The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. | Q35599843 | ||
| The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood | Q35629245 | ||
| Evidence of neuronal oxidative damage in Alzheimer's disease. | Q35782389 | ||
| Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology | Q35813745 | ||
| Immunohistochemical localization of a macrophage-specific antigen in developing mouse retina: phagocytosis of dying neurons and differentiation of microglial cells to form a regular array in the plexiform layers | Q36207544 | ||
| Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation | Q36231523 | ||
| Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease | Q36337525 | ||
| Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study | Q36613964 | ||
| Neuroinflammatory phenotype in early Alzheimer's disease | Q36629135 | ||
| The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging | Q36677808 | ||
| Effect of Alzheimer's disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study | Q36723845 | ||
| Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain | Q37053459 | ||
| Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: the Cache County Study | Q37199294 | ||
| Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies | Q37340312 | ||
| Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia | Q37363664 | ||
| Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice | Q37411415 | ||
| The multifaceted profile of activated microglia. | Q37560782 | ||
| Assessing activation states in microglia | Q37703293 | ||
| Microglia and inflammation in Alzheimer's disease | Q37703295 | ||
| Microglia phenotype diversity. | Q37818405 | ||
| Immune surveillance in the central nervous system | Q38029971 | ||
| TH2 cytokines and allergic challenge induce Ym1 expression in macrophages by a STAT6-dependent mechanism. | Q38363241 | ||
| Functional plasticity of microglia: a review | Q38596425 | ||
| Risk of Alzheimer's disease and duration of NSAID use. | Q39457609 | ||
| Aging enhances classical activation but mitigates alternative activation in the central nervous system | Q40644711 | ||
| Alzheimer's beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia | Q40997681 | ||
| The microglial cell. A historical review | Q41144699 | ||
| Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study | Q41919048 | ||
| A changing perspective on the role of neuroinflammation in Alzheimer's disease | Q42247119 | ||
| Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology | Q42276637 | ||
| Microglia derived from aging mice exhibit an altered inflammatory profile. | Q42506339 | ||
| Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid | Q42755604 | ||
| In-vivo measurement of activated microglia in dementia | Q43713539 | ||
| Temporal expression of different pathways of 1-arginine metabolism in healing wounds | Q43753508 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| heterogeneity | Q928498 | ||
| Alzheimer's disease | Q11081 | ||
| neuronitis | Q17157137 | ||
| P304 | page(s) | 103-11 | |
| P577 | publication date | 2015-08-27 | |
| P1433 | published in | Neuroscience | Q15708571 |
| P1476 | title | Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy | |
| P478 | volume | 302 |
| Q29248210 | A Bacterial Component to Alzheimer’s-Type Dementia Seen via a Systems Biology Approach that Links Iron Dysregulation and Inflammagen Shedding to Disease |
| Q36326816 | A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders |
| Q36027275 | A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice |
| Q92255438 | Abnormal gut microbiota composition contributes to cognitive dysfunction in streptozotocin-induced diabetic mice |
| Q35957099 | Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease |
| Q93047427 | Age-Related Changes in Immune Cells of the Human Cochlea |
| Q52644596 | Alzheimer's Disease, Oligomers, and Inflammation. |
| Q47700520 | Alzheimer's disease and cytokine IL-10 gene polymorphisms: is there an association? |
| Q34753579 | Alzheimer's disease and infections, where we stand and where we go. |
| Q35907609 | An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease |
| Q64275812 | Anti-Inflammatory Activity of A Polyphenolic Extract from in In Vitro and In Vivo Models of Alzheimer's Disease |
| Q38795492 | Astrocytes: inexplicable cells in neurodegeneration |
| Q35667387 | Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation |
| Q35990600 | Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. |
| Q42085409 | Copper Exposure Perturbs Brain Inflammatory Responses and Impairs Clearance of Amyloid-Beta |
| Q26781090 | Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease |
| Q48791445 | Depiction of microglial activation in aging and dementia: Positron emission tomography with [11C]DPA713 versus [11C]( R)PK11195. |
| Q60045755 | Dietary intake of pantothenic acid is associated with cerebral amyloid burden in patients with cognitive impairment |
| Q58605846 | Early microglial activation and peripheral inflammation in dementia with Lewy bodies |
| Q36210852 | Exercise-mimetic AICAR transiently benefits brain function |
| Q55416682 | Exosomes: a novel therapeutic target for Alzheimer's disease? |
| Q39021109 | Glucocorticoid-Induced Leucine Zipper in Central Nervous System Health and Disease |
| Q64100321 | Herpes Simplex Virus Type 1 Infection of the Central Nervous System: Insights Into Proposed Interrelationships With Neurodegenerative Disorders |
| Q90862831 | History and progress of hypotheses and clinical trials for Alzheimer's disease |
| Q42245222 | Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration |
| Q57816569 | Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer's Disease |
| Q38790379 | Inflammatory Response in the CNS: Friend or Foe? |
| Q37630548 | Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits |
| Q93051125 | Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer's Disease |
| Q91773883 | Malva parviflora extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer's disease by restoring microglial function via a PPAR-γ-dependent mechanism |
| Q30885784 | Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions |
| Q35733491 | More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. |
| Q98280964 | Multiscale causal networks identify VGF as a key regulator of Alzheimer's disease |
| Q37394743 | N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. |
| Q37576743 | Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses |
| Q28072386 | Neuroprotection via Reduction in Stress: Altered Menstrual Patterns as a Marker for Stress and Implications for Long-Term Neurologic Health in Women |
| Q37628345 | Neuroprotective Effects of Aged Garlic Extract on Cognitive Dysfunction and Neuroinflammation Induced by β-Amyloid in Rats |
| Q38921866 | Oral inflammation and infection, and chronic medical diseases: implications for the elderly. |
| Q27023315 | Oxidized cholesterol as the driving force behind the development of Alzheimer's disease |
| Q30235369 | Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis |
| Q39009840 | Pharmacological Effects of Active Components of Chinese Herbal Medicine in the Treatment of Alzheimer's Disease: A Review |
| Q42003365 | Plant polyphenols as inhibitors of NF-κB induced cytokine production-a potential anti-inflammatory treatment for Alzheimer's disease? |
| Q38640751 | Polymorphonuclear Neutrophil Functions are Differentially Altered in Amnestic Mild Cognitive Impairment and Mild Alzheimer's Disease Patients |
| Q45741541 | Profiling microRNA from Brain by Microarray in a Transgenic Mouse Model of Alzheimer's Disease. |
| Q64929938 | Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses. |
| Q30378420 | Synonymous variants in HTRA1 implicated in AMD susceptibility impair its capacity to regulate TGF-β signaling. |
| Q46251905 | The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases |
| Q38671719 | The Lipoxygenases: Their Regulation and Implication in Alzheimer's Disease. |
| Q38555411 | The Role of PGRN in Alzheimer's Disease |
| Q38529627 | The Role of TDP-43 in Alzheimer's Disease |
| Q30362129 | The Second Brain: Is the Gut Microbiota a Link Between Obesity and Central Nervous System Disorders? |
| Q26750987 | The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ |
| Q90211035 | Tocotrienol Rich Fraction Supplementation Modulate Brain Hippocampal Gene Expression in APPswe/PS1dE9 Alzheimer's Disease Mouse Model |
| Q94544697 | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer's Disease |
| Q38693735 | Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer's disease |
| Q36546334 | Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS) |
Search more.